Top

Published in:

Open Access 01-12-2015 | Editorial

Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects

Authors: Mikhail A Panteleev, Hendrik Coenraad Hemker

Published in: Thrombosis Journal | Issue 1/2015

Excerpt

Laboratory testing in hemostasis is a subject of growing concern among the specialists. To put it plainly, the standard assays that have been in widespread use for more than 40 years (APTT and PT assays for clotting, aggregometry for platelets) are not sensitive and specific for too many major disorders of hemostasis; their parameters can remain within normal ranges when patient is in acute danger of thrombosis or bleeding; even if they do detect some abnormality they do not indicate the severity of the clinical manifestations; in rare cases they are even abnormal in a clinically asymptomatic individual. …

Shah PK. Biomarkers of plaque instability. Curr Cardiol Rep. 2014;16:547.PubMedCrossRef

Gandara E, Kovacs MJ, Kahn SR, Wells PS, Anderson DA, Chagnon I, et al. Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb Haemost. 2013;110:1172–9.PubMedCrossRef

O’Donnell J, Boulton FE, Laffan MA. The relationship between plasma concentration of alpha2-macroglobulin and ABO blood group. Thromb Haemost. 2002;88:167–8.PubMed

Dentali F, Sironi AP, Ageno W, Bonfanti C, Crestani S, Frattini F, et al. Relationship between ABO blood group and hemorrhage: a systematic literature review and meta-analysis. Semin Thromb Hemost. 2013;39:72–82.PubMedCrossRef

Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol. 1994;88:601–7.PubMedCrossRef

Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122:1873–80.PubMedCentralPubMedCrossRef

Lipets E, Vlasova O, Urnova E, Margolin O, Soloveva A, Ostapushchenko O, et al. Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients. PLoS One. 2014;9:e87692.PubMedCentralPubMedCrossRef

Minnema MC, Peters RJ, de Winter R, Lubbers YP, Barzegar S, Bauer KA, et al. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20:2489–93.PubMedCrossRef

Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated FXII in survivors of myocardial infarction–association with circulating risk factors and extent of coronary artery disease. Thromb Haemost. 1998;79:14–8.PubMed

10.

Panteleev MA, Vasil’ev SA, Sinauridze EI, Vorobyev AI, Ataullakhanov FI. Practical Coagulation Science [in Russian]. Moscow; 2010.

11.

Al Dieri R, Alban S, Beguin S, Hemker HC. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost. 2006;4:83–9.PubMedCrossRef

12.

Danforth CM, Orfeo T, Everse SJ, Mann KG, Brummel-Ziedins KE. Defining the boundaries of normal thrombin generation: investigations into hemostasis. PLoS One. 2012;7:e30385.PubMedCentralPubMedCrossRef

13.

Tarandovskiy ID, Balandina AN, Kopylov KG, Konyashina NI, Kumskova MA, Panteleev MA, et al. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res. 2013;131:e274–80.PubMedCrossRef

14.

Brummel-Ziedins KE, Wolberg AS. Global assays of hemostasis. Curr Opin Hematol. 2014;21:395–403.PubMedCrossRef

15.

van Geffen M, van Heerde WL. Global haemostasis assays, from bench to bedside. Thromb Res. 2012;129:681–7.PubMedCrossRef

16.

Hemker HC, Al Dieri R, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol. 2004;11:170–5.PubMedCrossRef

17.

Eilertsen AL, Liestol S, Mowinckel MC, Hemker HC, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost. 2007;97:938–43.PubMed

18.

Yamaguchi Y, Moriki T, Igari A, Matsubara Y, Ohnishi T, Hosokawa K, et al. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. Thromb Res. 2013;132:263–70.PubMedCrossRef

19.

Brinkman HJM. Global assays and the management of oral anticoagulation. Thromb J. 2014, This collection: in press.

20.

Lance M. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J. 2014, This collection: in press.

21.

Lipets EN, Ataullakhanov FI. Global assays of hemostasis in the diagnostics of coagulation and evaluation of thrombosis risks. Thromb J. 2014, This collection: in press.

22.

Tynngard N, Lindahl TL, Ramstrom S. Assays of different aspects of hemostasis – what do they measure? Thromb J. 2014, This collection: in press.

23.

Dashkevich NM, Vuimo TA, Ovsepyan RA, Surov SS, Soshitova NP, Panteleev MA, et al. Effect of pre-analytical conditions on the thrombodynamics assay. Thromb Res. 2014;133:472–6.PubMedCrossRef

24.

Curvers J, Christella M, Thomassen LG, de Ronde H, Bertina RM, Rosendaal FR, et al. Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay. Thromb Haemost. 2002;87:483–92.PubMed

25.

Dargaud Y, Wolberg AS, Luddington R, Regnault V, Spronk H, Baglin T, et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res. 2012;130:929–34.PubMedCrossRef

26.

Brummel-Ziedins KE, Orfeo T, Rosendaal FR, Undas A, Rivard GE, Butenas S, et al. Empirical and theoretical phenotypic discrimination. J Thromb Haemost. 2009;7 Suppl 1:181–6.PubMedCentralPubMedCrossRef

27.

Hemker HC, Kerdelo S, Kremers RM. Is there value in kinetic modeling of thrombin generation? No (unless…). J Thromb Haemost. 2012;10:1470–7.PubMedCrossRef

28.

Willems GM, Lindhout T, Hermens WT, Hemker HC. Simulation model for thrombin generation in plasma. Haemostasis. 1991;21:197–207.PubMed

Title: Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects
Authors: Mikhail A Panteleev
Hendrik Coenraad Hemker
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Thrombosis Journal / Issue 1/2015
Electronic ISSN: 1477-9560
DOI: https://doi.org/10.1186/s12959-014-0032-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study

A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery

Family history of venous thromboembolism is a risk factor for venous thromboembolism in combined oral contraceptive users: a nationwide case-control study

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program

A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness

Autoinflammatory diseases: a possible cause of thrombosis?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page